Genmab A/S (GMAB)
After hours:
| Previous close | 32.39 |
| Open | 31.78 |
| Bid | 31.41 x 1800 |
| Ask | 33.95 x 1200 |
| Day's range | 31.29 - 31.85 |
| 52-week range | 26.19 - 49.07 |
| Volume | |
| Avg. volume | 687,411 |
| Market cap | 20.597B |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 61.90 |
| EPS (TTM) | 0.51 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 40.70 |
- GlobeNewswire
Transactions in connection with share buy-back program
Company Announcement COPENHAGEN, Denmark; June 27, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than August 31, 2022 and comprises up to 370,000 shares. The following transactions were executed under the program from June 20, 2022 to June 24, 2022: No. of
- GlobeNewswire
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in
- GlobeNewswire
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has informed us that, as of June 15, 2022 Wellington Management Group LLP had decreased their holding of shares in Genmab A/S to 4.99% of the share capital and voting rights in Genmab A/S, so that through shares and financial instruments they held the voting
